Suprachiasmatic modulation of noradrenaline release in the ventrolateral preoptic nucleus. 2007

Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
Département de Neurosciences Fondamentales, Centre Médical Universitaire, 1211 Genève 4, Switzerland.

As the major brain circadian pacemaker, the suprachiasmatic nucleus (SCN) is known to influence the timing of sleep and waking. We thus investigated here the effect of SCN stimulation on neurons of the ventrolateral preoptic nucleus (VLPO) thought to be involved in promoting sleep. Using an acute in vitro preparation of the rat anterior hypothalamus/preoptic area, we found that whereas single-pulse stimulations of the SCN evoked standard fast ionotropic IPSPs and EPSPs, train stimulations unexpectedly evoked a long-lasting inhibition (LLI). Such LLIs could also be evoked in VLPO neurons by pressure application of NMDA within the SCN, indicating the specific activation of SCN neurons. This LLI was shown to result from the presynaptic facilitation of noradrenaline release, because it was suppressed in presence of yohimbine, a selective antagonist of alpha2-adrenoreceptors. The LLI depended on the opening of a potassium conductance, because it was annulled at E(K) and could be reversed below E(K). These results show that the SCN can provide an LLI of the sleep-promoting VLPO neurons that could play a role in the circadian organization of the sleep-waking cycle.

UI MeSH Term Description Entries
D009433 Neural Inhibition The function of opposing or restraining the excitation of neurons or their target excitable cells. Inhibition, Neural
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D011301 Preoptic Area Region of hypothalamus between the ANTERIOR COMMISSURE and OPTIC CHIASM. Area Preoptica,Lateral Preoptic Area,Medial Preoptic Area,Preoptic Nuclei,Area Preopticas,Area, Lateral Preoptic,Area, Medial Preoptic,Area, Preoptic,Areas, Lateral Preoptic,Areas, Medial Preoptic,Areas, Preoptic,Lateral Preoptic Areas,Medial Preoptic Areas,Nuclei, Preoptic,Nucleus, Preoptic,Preoptic Area, Lateral,Preoptic Area, Medial,Preoptic Areas,Preoptic Areas, Lateral,Preoptic Areas, Medial,Preoptic Nucleus,Preoptica, Area,Preopticas, Area
D011810 Quinoxalines Quinoxaline
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
May 2003, Neuroscience letters,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
October 2001, The European journal of neuroscience,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
October 2002, The European journal of neuroscience,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
February 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
April 2017, Brain research bulletin,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
January 2000, Neuroreport,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
May 2003, Brain research bulletin,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
April 2017, Brain structure & function,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
November 2010, The Journal of physiology,
Benoît Saint-Mleux, and Laurence Bayer, and Emmanuel Eggermann, and Barbara E Jones, and Michel Mühlethaler, and Mauro Serafin
October 2003, Brain research,
Copied contents to your clipboard!